# Intravenous Labetalol Versus Hydralazine in Preeclampsia

> **NCT06360601** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tanta University** · enrollment: 40 (estimated)

## Conditions studied

- Preeclampsia Severe

## Interventions

- **DRUG:** Labetalol Injection
- **DRUG:** HydrALAZINE Injection

## Key facts

- **NCT ID:** NCT06360601
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-01
- **Primary completion:** 2024-11-20
- **Final completion:** 2024-12-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360601, "Intravenous Labetalol Versus Hydralazine in Preeclampsia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06360601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*